26/01/2009 (Agence Europe) - The European Medicines Agency has recommended that a further contra-indication be added to the use of toremifene (Fareston), manufactured by Orion Pharma and authorised in the EU since 1996. This medicine, used in the treatment of metastatic breast cancer in post-menopausal women, can lead to increased heart risk in women with heart rhythm abnormalities or with reduced left-ventricular ejection fraction (the heart cannot pump enough blood to the rest of the...